F. Grossi
University of Insubria · 19 works · 39 citations · h-index 2
Top works
- 973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
- P2.08.53 Safety Results of DEDALUS Trial: Sequential CT-IO, Hypofractionated RT and Consolidation IO in Unresectable Stage III NSCLC
- EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
- 125P Preliminary analysis on safety of the DEDALUS phase II trial: Induction chemo-durvalumab followed by reduced-dose radiotherapy and maintenance durvalumab for patients with unresectable stage III NSCLC
- 198TiP DEDALUS trial: A single-arm, phase II, multi-center study of chemo-immunotherapy followed by hypo-fractionated RT and maintenance immunotherapy in patients with unresectable stage III NSCLC
- 1963P Osimertinib efficacy in advanced non-small cell lung cancer (NSCLC) harboring different EGFR uncommon mutations: Real-world data from the Italian biomarker ATLAS database
- Osimertinib in advanced non-small cell lung cancer (NSCLC) harboring different EGFR uncommon variants: real-world data from the Italian biomarker ATLAS database
- 1974P Molecular signatures associated with poor-risk features in patients (pts) with EGFR-mutant (EGFR+) metastatic non-small cell lung cancer (mNSCLC): Real-world data from the ATLAS network
- P1.17.54 Long-Term Outcomes From Pembrolizumab in Patients With Advanced PD-L1 =50% NSCLC and Poor PS: A Transformer-Based AI Approach
- 43P First-line clinical outcomes of single versus compound EGFR PACC mutations in advanced NSCLC: An international multicentre study
- 69P Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
- 2031eP Impact of rebiopsy on treatment decisions and outcomes in EGFR-mutant NSCLCs progressing on first-line osimertinib
- 56P Pooled analysis of 4 studies evaluating weekly oral vinorelbine in patients with locally advanced or metastatic non-small cell lung cancer
- 33P Real-world experience of MET TKI-induced peripheral edema
- EP05.01-024 Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study